Zevalin combination shows positive results for non-Hodgkin's lymphoma

01/17/2008 | RTT News

Zevalin, an investigational radioimmunotherapy, combined with autologous stem cell transplantation and high-dose chemotherapy, had a 70% progression-free survival rate at two years in a Phase 2 study of non-Hodgkin's lymphoma patients who were ineligible for total-body irradiation, Cell Therapeutics announced. The study results will appear in the Journal of Clinical Oncology.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ